Cargando…
Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer
BACKGROUND: The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire for non-muscle invasive bladder cancer (QLQ-NMIBC24) has been available and applied for some years now, but has yet to undergo a full comprehensive psychometric evaluation. The aim of thi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452806/ https://www.ncbi.nlm.nih.gov/pubmed/34542736 http://dx.doi.org/10.1186/s41687-021-00372-4 |
_version_ | 1784570145888272384 |
---|---|
author | Ripping, Theodora M. Westhoff, Ellen Aaronson, Neil K. Van Hemelrijck, Mieke Rammant, Elke Witjes, J. Alfred Kiemeney, Lambertus. A. Aben, Katja K. H. Vrieling, Alina |
author_facet | Ripping, Theodora M. Westhoff, Ellen Aaronson, Neil K. Van Hemelrijck, Mieke Rammant, Elke Witjes, J. Alfred Kiemeney, Lambertus. A. Aben, Katja K. H. Vrieling, Alina |
author_sort | Ripping, Theodora M. |
collection | PubMed |
description | BACKGROUND: The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire for non-muscle invasive bladder cancer (QLQ-NMIBC24) has been available and applied for some years now, but has yet to undergo a full comprehensive psychometric evaluation. The aim of this study was to investigate the psychometric properties of the Dutch version of the EORTC QLQ-NMIBC24 questionnaire in patients with low, intermediate and high risk NMIBC. METHODS: We included patients newly diagnosed with NMIBC participating in the multicenter, population-based prospective cohort studies UroLife or BlaZIB. Psychometric evaluation included examination of the structural validity, reliability (i.e. internal consistency and test–retest reliability), construct validity (i.e. divergent validity and known-groups validity), responsiveness and interpretability. RESULTS: A total of 1463 patients who completed the baseline questionnaire of UroLife (n = 541, response rate 50%) or BlaZIB (n = 922, response rate 58%) were included. The percentage of missing responses were low for all non-sex related scales (< 1%) and ranged between 6.9% to 50.0% for sex-related scales. More than 15% of the patients obtained the lowest possible scores on nearly each scale (floor effect). The structural validity was adequate; the confirmatory factor analysis showed satisfactory results and all items of multiple items scales had higher within- than between-scale correlations. Reliability of the questionnaire was adequate for most multiple item scales (Cronbach’s α ≥ 0.70 and intraclass correlation coefficient ≥ 0.70), with exception of the scales ‘malaise’ and ‘bloating and flatulence’. The questionnaire also showed good construct validity; it showed low correlations with the items of the EORTC core questionnaire and was able to measure differences between risk-based subgroups. The responsiveness of the questionnaire was good, but the interpretability, i.e. minimal important change, could not be determined. CONCLUSIONS: This study shows that the measurement properties of the EORTC QLQL-NMIBC24 are good; it has a good structural validity, reliability (i.e. internal consistency and test–retest reliability), construct validity (i.e. divergent validity and known-group validity), and responsiveness. Interpretability could not be assessed. This questionnaire can be used to measure and monitor health-related quality of life of patients with NMIBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41687-021-00372-4. |
format | Online Article Text |
id | pubmed-8452806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-84528062021-10-07 Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer Ripping, Theodora M. Westhoff, Ellen Aaronson, Neil K. Van Hemelrijck, Mieke Rammant, Elke Witjes, J. Alfred Kiemeney, Lambertus. A. Aben, Katja K. H. Vrieling, Alina J Patient Rep Outcomes Research BACKGROUND: The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire for non-muscle invasive bladder cancer (QLQ-NMIBC24) has been available and applied for some years now, but has yet to undergo a full comprehensive psychometric evaluation. The aim of this study was to investigate the psychometric properties of the Dutch version of the EORTC QLQ-NMIBC24 questionnaire in patients with low, intermediate and high risk NMIBC. METHODS: We included patients newly diagnosed with NMIBC participating in the multicenter, population-based prospective cohort studies UroLife or BlaZIB. Psychometric evaluation included examination of the structural validity, reliability (i.e. internal consistency and test–retest reliability), construct validity (i.e. divergent validity and known-groups validity), responsiveness and interpretability. RESULTS: A total of 1463 patients who completed the baseline questionnaire of UroLife (n = 541, response rate 50%) or BlaZIB (n = 922, response rate 58%) were included. The percentage of missing responses were low for all non-sex related scales (< 1%) and ranged between 6.9% to 50.0% for sex-related scales. More than 15% of the patients obtained the lowest possible scores on nearly each scale (floor effect). The structural validity was adequate; the confirmatory factor analysis showed satisfactory results and all items of multiple items scales had higher within- than between-scale correlations. Reliability of the questionnaire was adequate for most multiple item scales (Cronbach’s α ≥ 0.70 and intraclass correlation coefficient ≥ 0.70), with exception of the scales ‘malaise’ and ‘bloating and flatulence’. The questionnaire also showed good construct validity; it showed low correlations with the items of the EORTC core questionnaire and was able to measure differences between risk-based subgroups. The responsiveness of the questionnaire was good, but the interpretability, i.e. minimal important change, could not be determined. CONCLUSIONS: This study shows that the measurement properties of the EORTC QLQL-NMIBC24 are good; it has a good structural validity, reliability (i.e. internal consistency and test–retest reliability), construct validity (i.e. divergent validity and known-group validity), and responsiveness. Interpretability could not be assessed. This questionnaire can be used to measure and monitor health-related quality of life of patients with NMIBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41687-021-00372-4. Springer International Publishing 2021-09-20 /pmc/articles/PMC8452806/ /pubmed/34542736 http://dx.doi.org/10.1186/s41687-021-00372-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Ripping, Theodora M. Westhoff, Ellen Aaronson, Neil K. Van Hemelrijck, Mieke Rammant, Elke Witjes, J. Alfred Kiemeney, Lambertus. A. Aben, Katja K. H. Vrieling, Alina Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer |
title | Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer |
title_full | Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer |
title_fullStr | Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer |
title_full_unstemmed | Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer |
title_short | Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer |
title_sort | validation and reliability of the dutch version of the eortc qlq-nmibc24 questionnaire module for patients with non-muscle-invasive bladder cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452806/ https://www.ncbi.nlm.nih.gov/pubmed/34542736 http://dx.doi.org/10.1186/s41687-021-00372-4 |
work_keys_str_mv | AT rippingtheodoram validationandreliabilityofthedutchversionoftheeortcqlqnmibc24questionnairemoduleforpatientswithnonmuscleinvasivebladdercancer AT westhoffellen validationandreliabilityofthedutchversionoftheeortcqlqnmibc24questionnairemoduleforpatientswithnonmuscleinvasivebladdercancer AT aaronsonneilk validationandreliabilityofthedutchversionoftheeortcqlqnmibc24questionnairemoduleforpatientswithnonmuscleinvasivebladdercancer AT vanhemelrijckmieke validationandreliabilityofthedutchversionoftheeortcqlqnmibc24questionnairemoduleforpatientswithnonmuscleinvasivebladdercancer AT rammantelke validationandreliabilityofthedutchversionoftheeortcqlqnmibc24questionnairemoduleforpatientswithnonmuscleinvasivebladdercancer AT witjesjalfred validationandreliabilityofthedutchversionoftheeortcqlqnmibc24questionnairemoduleforpatientswithnonmuscleinvasivebladdercancer AT kiemeneylambertusa validationandreliabilityofthedutchversionoftheeortcqlqnmibc24questionnairemoduleforpatientswithnonmuscleinvasivebladdercancer AT abenkatjakh validationandreliabilityofthedutchversionoftheeortcqlqnmibc24questionnairemoduleforpatientswithnonmuscleinvasivebladdercancer AT vrielingalina validationandreliabilityofthedutchversionoftheeortcqlqnmibc24questionnairemoduleforpatientswithnonmuscleinvasivebladdercancer |